低危甲状腺癌消融后结局:ESTIMABL1随机3期等效性试验5年随访
ESTIMABL1是一项在法国24个中心开展的多中心随机开放标签等效性试验,纳入低危分化型甲状腺癌全甲状腺切除术后成人患者,比较两种促甲状腺激素刺激方式(rhTSH或甲状腺激素撤药)与两种放射性碘活度(1·1 GBq或3·7 GBq)的四种组合策略。5年随访结果显示,726例患者中715例(98%)无疾病证据,疾病复发与消融策略无关,数据支持低危甲状腺癌术后使用1·1 GBq放射性碘联合rhTSH进行消融。
要点
- 5年随访时98%(715/726)患者无疾病证据。
- 11例有结构性疾病、甲状腺球蛋白升高或超声不确定发现。
- 疾病复发与消融策略无关,支持1·1 GBq放射性碘联合rhTSH。
核心结论
- 研究结果提示疾病复发与消融策略无关,数据验证了低危甲状腺癌术后使用1·1 GBq放射性碘联合rhTSH进行消融的合理性。
研究设计与样本
- 多中心、随机、开放标签、等效性试验,在法国24个中心开展。
- 2007年3月28日至2010年2月25日随机分配(1:1:1:1)低危分化型甲状腺癌全甲状腺切除术后成人患者。
- 四种策略组合两种促甲状腺激素刺激方式(rhTSH或甲状腺激素撤药)与两种放射性碘活度(1·1 GBq或3·7 GBq)。
- 随访包括每年左甲状腺素治疗下血清甲状腺球蛋白测定,rhTSH刺激后甲状腺球蛋白和颈部超声由治疗医生酌情进行。
- 726例患者( originally randomized 752例的97%)被随访,随机化后中位随访5·4年(范围0·5-9·2)。
主要发现
- 715例(98%)无疾病证据;其余11例中结构性疾病4例、血清甲状腺球蛋白升高5例、颈部超声不确定发现2例。
- 这11例中,消融时6例接受1·1 GBq放射性碘(5例rhTSH后、1例撤药后),5例接受3·7 GBq(2例rhTSH后、3例撤药后)。
- 消融时TSH刺激后甲状腺球蛋白浓度对消融时结构性疾病状态、6-10个月消融状态和最终结局有预后价值。
关键数值与推荐
- 完全甲状腺消融定义为rhTSH刺激后血清甲状腺球蛋白≤1 ng/mL且颈部超声正常(6-10个月时92%患者达到)。
- 无疾病证据定义为左甲状腺素治疗下血清甲状腺球蛋白≤1 ng/mL且颈部超声正常(当进行时)。
- 低活性1·1 GBq与高活性3·7 GBq之间、rhTSH注射与甲状腺激素撤药之间显示等效。
临床怎么用
- 低危甲状腺癌术后可采用1·1 GBq放射性碘联合rhTSH进行消融。
- 消融时TSH刺激后甲状腺球蛋白浓度可用于预后评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131I) administration after complete surgical resection in patients with low-risk thyroid cancer, 92% of patients had complete thyroid ablation at 6-10 months, defined as a recombinant human thyroid-stimulating hormone (rhTSH)-stimulated serum thyroglobulin concentration of 1 ng/mL or less and normal findings on neck ultrasonography. Equivalence was shown between low-activity (1·1 GBq) and high-activity (3·7 GBq) radioactive iodine and also between the use of rhTSH injections and thyroid hormone withdrawal. Here, we report outcomes after 5 years of follow-up. METHODS: This multicentre, randomised, open-label, equivalence trial was done at 24 centres in France. Between March 28, 2007, and Feb 25, 2010, we randomly assigned (1:1:1:1) adults with low-risk differentiated thyroid carcinoma who had undergone total thyroidectomy to one of four strategies, each combining one of two methods of thyrotropin stimulation (rhTSH or thyroid hormone withdrawal) and one of two radioactive iodine activities (1·1 GBq or 3·7 GBq). Randomisation was by computer-generated sequence, with variable block size. Follow-up consisted of a yearly serum thyroglobulin measurement on levothyroxine treatment. Measurement of rhTSH-stimulated thyroglobulin and neck ultrasonography were done at the discretion of the treating physician. No evidence of disease was defined as serum thyroglobulin of 1 ng/mL or less on levothyroxine treatment and normal results on neck ultrasonography, when performed. This study was registered with ClinicalTrials.gov, number NCT00435851. FINDINGS: 726 patients (97% of the 752 patients originally randomised) were followed up. At a median follow-up since randomisation of 5·4 years (range 0·5-9·2), 715 (98%) had no evidence of disease. The other 11 had either structural disease (n=4), raised serum thyroglobulin concentration (n=5), or indeterminate findings on neck ultrasonography (n=2). At ablation, six of these patients had received 1·1 GBq radioactive iodine (five after rhTSH and one after withdrawal) and five had received 3·7 GBq (two after rhTSH and three after withdrawal). TSH-stimulated (either after rhTSH injections or thyroid hormone withdrawal according to the treatment group) thyroglobulin concentration measured at the time of ablation was prognostic for structural disease status at ablation, ablation status at 6-10 months, and the final outcome. INTERPRETATION: Our findings suggest that disease recurrence was not related to the strategy used for ablation. These data validate the use of 1·1 GBq radioactive iodine after rhTSH for postoperative ablation in patients with low-risk thyroid cancer. FUNDING: French National Cancer Institute (INCa), French Ministry of Health, and Sanofi Genzyme.
引用
- Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 2018. PMID: 29807824. doi:10.1016/S2213-8587(18)30113-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。